Small molecule · Modulator of androgen receptor (AR) · developed by OPKO Health
LY2452473 is an orally bioavailable selective androgen receptor modulator (SARM). It binds the androgen receptor, acting as an agonist in skeletal muscle, bone and the penis and as an antagonist in the prostate. It is studied in benign prostatic hyperplasia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03297398 | Phase 2 | Benign Prostatic Hyperplasia | Terminated | OPK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Benign Prostatic Hyperplasia
See OPK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
OPK catalysts and pipeline →